Silence Therapeutics News

Buy Rating on Silence Therapeutics: Positive Phase 2 Data and Potential for Blockbuster Revenues

TipRanks00:45

Chardan Capital: Maintains Silence Therapeutics (SLN.US) rating, adjusted from buy to buy rating, and adjusted target price from $42.00 to $42.00.

Zhitong FinanceMay 17 20:50

Silence Therapeutics Analyst Ratings

BenzingaMay 17 20:48

Damo: Maintaining the Silence Therapeutics (SLN.US) rating, adjusted from an increase holdings to an increase rating, and the target price was adjusted from $45.00 to $45.00.

Zhitong FinanceApr 23 01:30

Silence Therapeutics Analyst Ratings

BenzingaApr 23 01:29

Morgan Stanley Maintains Overweight on Silence Therapeutics, Maintains $45 Price Target

BenzingaApr 23 01:29

Silence Therapeutics Analyst Ratings

BenzingaMar 16 00:55

Silence Therapeutics Analyst Ratings

BenzingaMar 15 00:32

Morgan Stanley Boosts Price Target on Silence Therapeutics to $45 From $29, Says Q4 Showed 'Meaningful Progress,' Keeps Overweight Rating

MT NewswiresMar 14 19:57

Chardan Capital Maintains Buy on Silence Therapeutics, Raises Price Target to $42

BenzingaMar 14 19:54

Silence Therapeutics Analyst Ratings

BenzingaMar 13 23:33

Bullish on Silence Therapeutics: Buy Rating Affirmed Amid Strong Phase 2 Results for Zerlasiran

TipRanksMar 13 22:55

Silence Therapeutics Analyst Ratings

BenzingaFeb 22 22:02

Analysts Offer Insights on Healthcare Companies: Silence Therapeutics (SLN) and Aurinia Pharmaceuticals (AUPH)

TipRanksFeb 22 19:30

Analysts Offer Insights on Healthcare Companies: Healthcare Services (HCSG), Gritstone Oncology (GRTS) and Silence Therapeutics (SLN)

TipRanksFeb 13 20:30

Silence Therapeutics Analyst Ratings

BenzingaJan 31 18:58

Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Silence Therapeutics (SLN) and Dyne Therapeutics (DYN)

TipRanksJan 31 14:00

Buy Rating for Silence Therapeutics: Strong Prospects for RNAi Platform and Drug Candidates

TipRanksJan 23 04:35

HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target

BenzingaJan 18 19:08

Silence Therapeutics Analyst Ratings

BenzingaJan 18 19:07